4-Chloro-2-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl]methyl]phenyl chloroformate | 234433-31-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-2-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl]methyl]phenyl chloroformate
• 英文别名: [4-chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenyl] carbonochloridate
• CAS: 234433-31-9
• 化学式: C₁₇H₉Cl₂F₃N₂O₄
• 分子量: 433.171
• InChiKey: ZMUBODXUVCNPDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-Chloro-2-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl]methyl]phenyl chloroformate 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 2-[4-Chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenoxy]carbonyloxyethyl-trimethylazanium;methanesulfonate
  参考文献：
  名称：

  Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

  摘要：

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00296-8
• 作为产物：
  描述：

  光气 、 3-(5-氯-2-羟基苄基)-5-(4-(三氟甲基)苯基)-1,3,4-噁二唑-2(3h)-酮 在 光气 、 甲苯 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以to afford the chlorotormate product as a white semi-solid (1.18 g)的产率得到4-Chloro-2-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl]methyl]phenyl chloroformate
  参考文献：
  名称：

  Derivatives of 1,3,4-oxadiazolone

  摘要：

  本发明提供了一种具有通式##STR1##中A、B、D和R的新型噁二唑酮衍生物，或其无毒且药学上可接受的盐或溶剂，可用于治疗对开放大电导钙激活钾通道有反应的疾病。

  公开号：

  US06034113A1

文献信息

• Derivatives of 1,3,4-oxadiazolone
  申请人：Bristol-Myers Squibb Company

  公开号：US06034113A1

  公开（公告）日：2000-03-07

  The present invention provides novel oxadiazolone derivatives having the general formula ##STR1## wherein A, B, D and R are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of the large conductance calcium-activated potassium channels.

  本发明提供了一种具有通式##STR1##中A、B、D和R的新型噁二唑酮衍生物，或其无毒且药学上可接受的盐或溶剂，可用于治疗对开放大电导钙激活钾通道有反应的疾病。
• US6034113A
  申请人：——

  公开号：US6034113A

  公开（公告）日：2000-03-07
• Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection
  作者：Piyasena Hewawasam、Min Ding、Nathan Chen、Dalton King、Jay Knipe、Lorraine Pajor、Astrid Ortiz、Valentin K. Gribkoff、John Starrett

  DOI：10.1016/s0960-894x(03)00296-8

  日期：2003.5

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.